Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.010
Sell
RSI(14)
40.966
Neutral
STOCH(KDJ)(9,3,3)
26.426
Neutral
ATR(14)
0.274
High Vlolatility
CCI(14)
-122.080
Sell
Williams %R
75.000
Sell
TRIX(12,20)
-0.486
Sell
StochRSI(14)
88.440
Buy
Precision BioSciences Inc
DTIL3.800USD
+0.230+6.44%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
45.91MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Precision BioSciences Inc
Currency: USD Updated: 2026-02-06Key Insights
Precision BioSciences Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 148 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 32.50.In the medium term, the stock price is expected to trend down.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Precision BioSciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Precision BioSciences Inc Highlights
StrengthsRisks
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 173.71% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 68.70M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -0.42, at a medium 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 196.18K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.91.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
32.500
Target Price
+810.36%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Precision BioSciences Inc is 5.62, ranking 343 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 13.00K, representing a year-over-year decrease of 97.74%, while its net profit experienced a year-over-year decrease of 32.55%.
Score
Financials
6.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.23
Operational Efficiency
2.83
Growth Potential
4.90
Shareholder Returns
7.07
Precision BioSciences Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Precision BioSciences Inc is 8.57, ranking 36 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.42, which is -1432.77% below the recent high of 5.65 and -373.74% above the recent low of -2.01.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 148/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Precision BioSciences Inc is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 25.50, with a high of 60.00 and a low of 19.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
32.500
Target Price
+810.36%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Precision BioSciences Inc
DTIL
4
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Precision BioSciences Inc is 4.80, ranking 340 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.43 and the support level at 3.35, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.812
Sell
MA10
3.913
Sell
MA20
3.997
Sell
MA50
4.380
Sell
MA100
5.184
Sell
MA200
5.026
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Precision BioSciences Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 36.99%, representing a quarter-over-quarter decrease of 47.59%. The largest institutional shareholder is The Vanguard, holding a total of 906.78K shares, representing 3.96% of shares outstanding, with 48.62% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Bleichroeder LP
Lynx1 Capital Advisors LLC
Readout Capital LP
Tang Capital Management, LLC
Novartis Pharma AG
Benjamin (Weinstein)
Smith (Matthew)
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Precision BioSciences Inc is 2.44, ranking 228 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.31. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.31
VaR
+7.80%
240-Day Maximum Drawdown
+58.54%
240-Day Volatility
+82.09%
Return
Best Daily Return
60 days
+6.46%
120 days
+15.46%
5 years
+29.63%
Worst Daily Return
60 days
-12.59%
120 days
-12.59%
5 years
-31.24%
Sharpe Ratio
60 days
-3.70
120 days
-0.53
5 years
-0.78
Risk Assessment
Maximum Drawdown
240 days
+58.54%
3 years
+86.92%
5 years
+99.16%
Return-to-Drawdown Ratio
240 days
-0.56
3 years
-0.31
5 years
-0.20
Skewness
240 days
+0.63
3 years
+0.70
5 years
+0.61
Volatility
Realised Volatility
240 days
+82.09%
5 years
+86.63%
Standardised True Range
240 days
+9.13%
5 years
+116.71%
Downside Risk-Adjusted Return
120 days
-82.25%
240 days
-82.25%
Maximum Daily Upside Volatility
60 days
+38.45%
Maximum Daily Downside Volatility
60 days
+45.33%
Liquidity
Average Turnover Rate
60 days
+2.68%
120 days
+2.06%
5 years
--
Turnover Deviation
20 days
-90.65%
60 days
-68.69%
120 days
-75.93%
Peer Comparison
Biotechnology & Medical Research
Precision BioSciences Inc
DTIL
5.99 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
